{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Liposarcoma", "query": { "condition": "Refractory Liposarcoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:27:03.223Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04213794", "title": "Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Malignant Abdominal Neoplasm", "Malignant Pelvic Neoplasm", "Recurrent Colon Carcinoma", "Recurrent Desmoplastic Small Round Cell Tumor", "Recurrent Fallopian Tube Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Liposarcoma", "Recurrent Malignant Mesothelioma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Rhabdomyosarcoma", "Recurrent Sarcoma", "Refractory Colon Carcinoma", "Refractory Desmoplastic Small Round Cell Tumor", "Refractory Fallopian Tube Carcinoma", "Refractory Gastric Carcinoma", "Refractory Liposarcoma", "Refractory Malignant Mesothelioma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma", "Refractory Rectal Carcinoma", "Refractory Rhabdomyosarcoma", "Refractory Sarcoma", "Resectable Liposarcoma", "Resectable Malignant Mesothelioma", "Resectable Sarcoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoreductive Surgery", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Hyperthermic Intraperitoneal Chemotherapy", "type": "DRUG" }, { "name": "Sodium Thiosulfate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 2, "start_date": "2019-11-08", "completion_date": "2024-10-03", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04213794" }, { "nct_id": "NCT01614795", "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Alveolar Soft Part Sarcoma", "Childhood Angiosarcoma", "Childhood Epithelioid Sarcoma", "Childhood Fibrosarcoma", "Childhood Gliosarcoma", "Childhood Leiomyosarcoma", "Childhood Liposarcoma", "Childhood Malignant Peripheral Nerve Sheath Tumor", "Childhood Synovial Sarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Osteosarcoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 46, "start_date": "2012-06-18", "completion_date": "2014-04-01", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614795" }, { "nct_id": "NCT04668300", "title": "Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Angiosarcoma", "Metastatic Dedifferentiated Liposarcoma", "Metastatic Osteosarcoma", "Recurrent Angiosarcoma", "Recurrent Dedifferentiated Liposarcoma", "Recurrent Osteosarcoma", "Refractory Dedifferentiated Liposarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oleclumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2020-11-26", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04668300" }, { "nct_id": "NCT06541262", "title": "Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Ewing Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma", "Liposarcoma" ], "interventions": [ { "name": "Silmitasertib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 104, "start_date": "2024-10-30", "completion_date": "2035-11-01", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06541262" }, { "nct_id": "NCT03600649", "title": "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Myxoid Liposarcoma", "Sarcoma,Soft Tissue", "Desmoplastic Small Round Cell Tumor", "Extraskeletal Myxoid Chondrosarcoma", "Angiomatoid Fibrous Histiocytoma", "Clear Cell Sarcoma", "Primary Pulmonary Myxoid Sarcoma", "Myoepithelial Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Fibromyxoid Tumor" ], "interventions": [ { "name": "Seclidemstat", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Salarius Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 50, "start_date": "2018-06-04", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Monica, California • Jacksonville, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600649" }, { "nct_id": "NCT03670069", "title": "Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Leiomyosarcoma", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Advanced Myxoid Liposarcoma", "Advanced Soft Tissue Sarcoma", "Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Soft Tissue Sarcoma", "Refractory Leiomyosarcoma", "Refractory Myxoid Liposarcoma", "Refractory Round Cell Liposarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Synovial Sarcoma", "Refractory Undifferentiated Pleomorphic Sarcoma", "Advanced Leiomyosarcoma", "Advanced Synovial Sarcoma", "Advanced Undifferentiated Pleomorphic Sarcoma", "Metastatic Chondrosarcoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-09-30", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670069" }, { "nct_id": "NCT03063632", "title": "Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Synovial Sarcoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Refractory Mycosis Fungoides and Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Interferon Gamma-1b", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 28, "start_date": "2017-12-14", "completion_date": "2023-03-14", "has_results": true, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 7, "location_summary": "Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03063632" }, { "nct_id": "NCT01532687", "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Undifferentiated Pleomorphic Sarcoma", "Malignant Adult Hemangiopericytoma", "Recurrent Adult Soft Tissue Sarcoma", "Sarcoma", "Stage III Adult Soft Tissue Sarcoma AJCC v7", "Stage IV Adult Soft Tissue Sarcoma AJCC v7" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2012-03-13", "completion_date": "2019-10-31", "has_results": true, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-05-21T22:27:03.223Z", "location_count": 2, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01532687" } ] }